The Howland Capital Management LLC Reduces Position in Merck & Co., Inc. (MRK)

The Howland Capital Management LLC Reduces Position in Merck & Co., Inc. (MRK)

A number of other large investors have also recently bought and sold shares of MRK. Intellectus Partners LLC bought a new position in shares of Merck & Co. during the fourth quarter valued at $103,000. Cascade Investment Advisors Inc. bought a new position in shares of Merck & Co. during the fourth quarter valued at $135,000. Mascoma Wealth Management LLC bought a new position in shares of Merck & Co. during the fourth quarter valued at $135,000. Gradient Investments LLC boosted its position in shares of Merck & Co. by 41.3% in the first quarter. Gradient Investments LLC now owns 2,306 shares of the company’s stock valued at $147,000 after buying an additional 674 shares in the last quarter. Finally, Pinnacle Bank bought a new position in shares of Merck & Co. during the first quarter valued at $152,000. Institutional investors own 74.10% of the company’s stock.

Howland Capital Management LLC lowered its stake in Merck & Co., Inc. (NYSE:MRK) by 1.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 48,957 shares of the company’s stock after selling 488 shares during the period. Howland Capital Management LLC’s holdings in Merck & Co. were worth $3,111,000 as of its most recent filing with the SEC.

Merck & Co., Inc. (NYSE:MRK) opened at 65.47 on Monday. The firm has a market capitalization of $179.07 billion, a PE ratio of 41.73 and a beta of 0.79. Merck & Co., Inc. has a 1-year low of $55.10 and a 1-year high of $66.80. The firm’s 50-day moving average price is $63.58 and its 200-day moving average price is $62.97.

Merck & Co. (NYSE:MRK) last posted its earnings results on Tuesday, May 2nd. The company reported $0.88 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.83 by $0.05. The business had revenue of $9.43 billion for the quarter, compared to analyst estimates of $9.25 billion. Merck & Co. had a net margin of 14.30% and a return on equity of 24.08%. The business’s quarterly revenue was up 1.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.89 EPS. On average, equities research analysts predict that Merck & Co., Inc. will post $3.84 EPS for the current fiscal year.

Several research analysts have recently weighed in on the company. Zacks Investment Research upgraded Merck & Co. from a “hold” rating to a “buy” rating and set a $73.00 target price on the stock in a report on Friday, May 26th. Jefferies Group LLC restated a “sell” rating and set a $51.00 target price on shares of Merck & Co. in a report on Wednesday, May 24th. Vetr cut Merck & Co. from a “strong-buy” rating to a “buy” rating and set a $69.99 target price on the stock. in a report on Wednesday, May 17th. JPMorgan Chase & Co. boosted their target price on Merck & Co. from $74.00 to $76.00 and gave the stock an “overweight” rating in a report on Thursday, May 11th. Finally, BMO Capital Markets boosted their target price on Merck & Co. from $68.00 to $70.00 and gave the stock an “outperform” rating in a report on Thursday, May 11th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $68.58. In related news, EVP Adam H. Schechter sold 53,850 shares of Merck & Co. stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $63.48, for a total transaction of $3,418,398.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director C Robert Kidder sold 5,000 shares of Merck & Co. stock in a transaction on Friday, May 12th. The shares were sold at an average price of $63.54, for a total transaction of $317,700.00. Following the transaction, the director now owns 14,317 shares in the company, valued at approximately $909,702.18. The disclosure for this sale can be found here. Insiders own 0.05% of the company’s stock.

Merck & Co. Company Profile Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “MRK”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Related posts

Leave a Comment